Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis

References

• Cystic Fibrosis Foundation. Available from: https://www.cff.org/. Accessed July 26, 2019.
   Google Scholar
• Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066–1073.2475911
   PubMed Web of Science ®Google Scholar
• Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem. 2008;77:701–726. doi:10.1146/annurev.biochem.75.103004.14253218304008
   PubMed Web of Science ®Google Scholar
• Anderson MP, Gregory RJ, Thomson S, et al. Demonstration that CFTR is a chloride channel by alteration of anion selectivity. Science. 1991;253:202–205.1712984
   PubMed Web of Science ®Google Scholar
• Smith JJ, Welsh MJ. cAMP stimulates bicarbonate secretion across normal, but not cystic fibrosis airway epithelia. J Clin Invest. 1992;89:1148–1153. doi:10.1172/JCI1156961313448
   PubMed Web of Science ®Google Scholar
• Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science. 1995;269:847–850.7543698
   PubMed Web of Science ®Google Scholar
• Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child. 1938;56:344. doi:10.1001/archpedi.1938.01980140114013
   Google Scholar
• Cystic Fibrosis Foundation. Patient registry: annual data report; 2017 Available from: https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2017-Patient-Registry-Annual-Data-Report.pdf. Accessed 605, 2019.
   Google Scholar
• JS E. Cystic Fibrosis. Lancet. 2016;383:2519–2531.
   Google Scholar
• Available from: www.CFTR2.org. Accessed July 26, 2019.
   Google Scholar
• Sosnay PR, Siklosi KR, Van Goor F, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013;45(10):1160–1167. doi:10.1038/ng.274523974870
   PubMed Web of Science ®Google Scholar
• Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration. 2000;67(2):117‐133. doi:10.1159/000067466
   PubMed Web of Science ®Google Scholar
• Oates GR, Schechter MS. Socioeconomic status and health outcomes: cystic fibrosis as a model. Expert Rev Respir Med. 2016;10(9):967–977. doi:10.1080/17476348.2016.119614027268142
   PubMed Web of Science ®Google Scholar
• Rafeeq MM, Murad HAS. Cystic fbrosis: current therapeutic targets and future approaches. J Transl Med. 2017;15(1):84. doi:10.1186/s12967-017-1193-928449677
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663–1672. doi:10.1056/NEJMoa110518522047557
   PubMed Web of Science ®Google Scholar
• Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013;187(11):1219–1225. doi:10.1164/rccm.201301-0153OC23590265
   PubMed Web of Science ®Google Scholar
• McKone EF, Borowitz D, Drevinek P, et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med. 2014;2(11):902–910. doi:10.1016/S2213-2600(14)70218-825311995
   PubMed Web of Science ®Google Scholar
• Bessonova L, Volkova N, Higgins M, et al. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax. 2018;73(8):731–740. doi:10.1136/thoraxjnl-2017-21039429748252
   PubMed Web of Science ®Google Scholar
• Faruqi S, Shiferaw D, Morice AH. Effect of ivacaftor on objective and subjective measures of cough in patients with cystic fibrosis. Open Respir Med J. 2016;10:105–108. doi:10.2174/187430640161001010528217196
   PubMedGoogle Scholar
• Zeybel GL, Pearson JP, Krishnan A, et al. Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation. J Cyst Fibros. 2017;16(1):124–131. doi:10.1016/j.jcf.2016.07.00427475719
   PubMed Web of Science ®Google Scholar
• Van Goor F, Yu H, Burton B, Hoffman BJ. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros. 2014;13(1):29–36. doi:10.1016/j.jcf.2013.06.00823891399
   PubMed Web of Science ®Google Scholar
• Flume PA, Kiou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508D- CFTR mutation. Chest. 2012;142:718–724. doi:10.1378/chest.11-267222383668
   PubMed Web of Science ®Google Scholar
• Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508D-cftr protein processing defect in vitro by the investigational drug vx-809. Proc Natl Acad Sci U S A. 2011;108:18843–18848. doi:10.1073/pnas.110578710821976485
   PubMed Web of Science ®Google Scholar
• Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508D-CFTR mutation. Thorax. 2012;67:12–18. doi:10.1136/thoraxjnl-2011-20039321825083
   PubMed Web of Science ®Google Scholar
• Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del cftr. N Engl J Med. 2015;373:220–231. doi:10.1056/NEJMoa140954725981758
   PubMed Web of Science ®Google Scholar
• Konstan MW, McKone EF, Moss RB, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508D-cftr mutation (PROGRESS): A phase 3, extension study. Lancet Respir Med. 2017;5(2):107–118. doi:10.1016/S2213-2600(16)30427-128011037
   PubMed Web of Science ®Google Scholar
• Rowe SM, McColley SA, Rietschel E, et al. Lumacaftor/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508D-cftr. Ann Am Thorac Soc. 2017;14(2):213–219. doi:10.1513/AnnalsATS.201609-689OC27898234
   PubMed Web of Science ®Google Scholar
• Van Goor F, Grootenhuis P, Hadida S, et al. Nonclinical profile of the CFTR corrector VX-661. Pediatr Pulmonol. 2016;51(S45):S194–S485. (abstract from conference proceedings [number 217]. doi:10.1002/ppul.23576)27653516
   PubMedGoogle Scholar
• Donaldson SH, Pilewski JM, Griese M, et al. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR. Am J Respir Crit Care Med. 2018;197(2):214–224. doi:10.1164/rccm.201704-0717OC28930490
   PubMed Web of Science ®Google Scholar
• Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med. 2017;377(21):2013–2023. doi:10.1056/NEJMoa170984629099344
   PubMed Web of Science ®Google Scholar
• Rowe SM, Daines C, Ringshausen FC, et al. Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med. 2017;377(21):2024–2035. doi:10.1056/NEJMoa170984729099333
   PubMed Web of Science ®Google Scholar
• Davies JC, Moskowitz SM, Brown C, et al. VX-659-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med. 2018;379(17):1599–1611. doi:10.1056/NEJMoa180711930334693
   PubMed Web of Science ®Google Scholar
• Keating D, Marigowda G, Burr L, et al. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med. 2018;379(17):1612–1620. doi:10.1056/NEJMoa180712030334692
   PubMed Web of Science ®Google Scholar
• Schneider EK. Cytochrome P450 3A4 induction: lumacaftor versus ivacaftor potentially resulting in significantly reduced plasma concentration of ivacaftor. Drug Metab Lett. 2018;12(1):71–77. doi:10.2174/187231281266618032810525929595119
   PubMedGoogle Scholar
• Garg V, Shen J, Li C, et al. Pharmacokinetic and drug-drug interaction profiles of the combination of tezacaftor/ivacaftor. Clin Transl Sci. 2019;12(3):267–275. doi:10.1111/cts.1261030694595
   PubMed Web of Science ®Google Scholar
• Mayer ML. umacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the ‘breakthrough’. BMJ Evidence Based Med. 2016;21:83–86. doi:10.1136/ebmed-2015-110325
   Google Scholar
• Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680–689.23540878
   PubMed Web of Science ®Google Scholar
• Cystic fibrosis: diagnosis and management: NICE guideline [NG78]; 10, 2017 Available from: https://www.nice.org.uk/guidance/ng78. Accesssed 26 July, 2019.
   Google Scholar
• Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The pulmozyme study group. N Engl J Med. 1994;331:637–642. doi:10.1056/NEJM1994070733101037503821
   PubMed Web of Science ®Google Scholar
• Yang C, Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2018;6(9):CD001127.
   Google Scholar
• Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354:229–240. doi:10.1056/NEJMoa04390016421364
   PubMed Web of Science ®Google Scholar
• Nevitt SJ, Thornton J, Murray CS, et al. Inhaled mannitol for cystic fibrosis. Cochrane Database Syst Rev. 2018;9(2):CD008649.
   Google Scholar
• Grootenhuis P, Van Goor F, Hadida S, et al. Discovery and biological profile of next-generation CFTR correctors. Pediatr Pulmonol. 2016;51(S45):S194–S485. (abstract from conference proceedings [number 188]. doi:10.1002/ppul.23576)27653516
   PubMedGoogle Scholar
• Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation. Technology appraisal guidance [TA398]; 7 27, 2016 Available from: https://www.nice.org.uk/guidance/ta398. Accessed 26 July, 2019.
   Google Scholar